Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?
暂无分享,去创建一个
[1] J. Tardif,et al. Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. , 2020, The New England journal of medicine.
[2] J. Witztum,et al. Statin therapy increases lipoprotein(a) levels. , 2020, European heart journal.
[3] J. Leipsic,et al. From Subclinical Atherosclerosis to Plaque Progression and Acute Coronary Events: JACC State-of-the-Art Review. , 2019, Journal of the American College of Cardiology.
[4] B. Nordestgaard,et al. High lipoprotein(a) and high risk of mortality. , 2019, European heart journal.
[5] M. Sabatine,et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. , 2019, European heart journal.
[6] B. Nordestgaard,et al. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. , 2019, Journal of the American College of Cardiology.
[7] W. Shen,et al. Lipoprotein (a) interactions with cholesterol-containing lipids on angiographic coronary collateralization in type 2 diabetic patients with chronic total occlusion , 2019, Cardiovascular Diabetology.
[8] B. Nordestgaard,et al. Antisense Oligonucleotides Targeting Lipoprotein(a) , 2019, Current Atherosclerosis Reports.
[9] M. Koschinsky,et al. Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. , 2022, Journal of clinical lipidology.
[10] R. Klingel,et al. Lipoprotein(a) and mortality—a high risk relationship , 2019, Clinical Research in Cardiology Supplements.
[11] A. Keech,et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.
[12] K. Parhofer,et al. Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a). , 2019, Pathology.
[13] Chao He,et al. Association of lipoprotein(a) and major adverse cardiovascular events in patients with percutaneous coronary intervention , 2018, Archives of medical science : AMS.
[14] A. Sahebkar,et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials , 2018, Scientific Reports.
[15] J. Ralphe,et al. In pediatric familial hypercholesterolemia, lipoprotein(a) is more predictive than LDL-C for early onset of cardiovascular disease in family members. , 2018, Journal of clinical lipidology.
[16] F. Kronenberg,et al. Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials , 2018, The Lancet.
[17] L. Tokgozoglu,et al. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. , 2018, Journal of the American College of Cardiology.
[18] G. Hillis,et al. Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease. , 2018, Journal of clinical lipidology.
[19] Cheng-gang Zhu,et al. Low-density lipoprotein-associated variables and the severity of coronary artery disease: an untreated Chinese cohort study , 2018, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[20] B. Nordestgaard,et al. Antiplatelet therapy: Pharmacogenomic approach to tailor drug therapy , 2018, Nature Reviews Cardiology.
[21] Jennifer G. Robinson,et al. Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis , 2018, JAMA.
[22] S. Crooke,et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.
[23] B. Nordestgaard,et al. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.
[24] Jennifer G. Robinson,et al. Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[25] D. Rader,et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial , 2015, The Lancet.
[26] Improve-It Investigators. Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .
[27] B. Nordestgaard,et al. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. , 2015, Clinical chemistry.
[28] F. Raal,et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial , 2015, The Lancet.
[29] R. Califf,et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.
[30] Sarah Parish,et al. Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.
[31] A. Khera,et al. Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.
[32] B. Nordestgaard,et al. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.
[33] W. Lehmacher,et al. Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study , 2013, Circulation.
[34] Kathleen F. Kerr,et al. Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.
[35] William Weintraub,et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. , 2011, The New England journal of medicine.
[36] G. Hansson,et al. The immune system in atherosclerosis , 2011, Nature Immunology.
[37] R. Collins,et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. , 2009, The New England journal of medicine.
[38] Stephen Kaptoge,et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.
[39] Børge G Nordestgaard,et al. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.
[40] J. Borén,et al. Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .
[41] Jonathan C. Cohen,et al. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.
[42] Eric Boerwinkle,et al. Sequence Variations in PCSK 9 , Low LDL , and Protection against Coronary Heart Disease , 2006 .
[43] J. Witztum,et al. Oxidized low density lipoprotein and innate immune receptors , 2003, Current opinion in lipidology.
[44] J. Weissenbach,et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.
[45] K. V. van Dijk,et al. Macrophage scavenger receptor class A: A multifunctional receptor in atherosclerosis. , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[46] R A Kronmal,et al. Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. , 1998, JAMA.
[47] S. Yusuf,et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations , 1992, Circulation.
[48] J. Goldstein,et al. Teaching old dogmas new tricks , 1987, Nature.
[49] M. Brown,et al. Plasma lipoproteins: teaching old dogmas new tricks. , 1987, Nature.
[50] S. Srinivasan,et al. Low density lipoprotein retention by aortic tissue. Contribution of extracellular matrix. , 1986, Atherosclerosis.
[51] M. Kuroda,et al. Citrinin, an inhibitor of cholesterol synthesis. , 1976, The Journal of antibiotics.
[52] M. Brown,et al. Binding and degradation of low density lipoproteins by cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia. , 1974, The Journal of biological chemistry.